We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
It's not easy being green; nor is it cheap. Reclaiming returned products requires investments in technology and labor. But there are a lot of good reasons to make the effort.
FDA approval came too late for last year's flu season. But Wyeth Pharmaceuticals plans to make up for lost time with this year's launch of its nasal influenza vaccine, FluMist. It's banking on a high-tech cold chain distribution network to make it happen.